FineMark National Bank & Trust Buys 760 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

FineMark National Bank & Trust grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,522 shares of the medical equipment provider’s stock after acquiring an additional 760 shares during the period. FineMark National Bank & Trust’s holdings in Intuitive Surgical were worth $7,935,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Baystate Wealth Management LLC boosted its stake in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the period. MCF Advisors LLC increased its position in shares of Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the period. Headinvest LLC acquired a new position in Intuitive Surgical in the third quarter valued at about $28,000. Stone House Investment Management LLC grew its stake in Intuitive Surgical by 100.0% during the third quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 50 shares in the last quarter. Finally, Truvestments Capital LLC raised its position in shares of Intuitive Surgical by 137.2% in the 3rd quarter. Truvestments Capital LLC now owns 102 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 59 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 148,290 shares of company stock worth $57,207,154. 0.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on ISRG shares. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. BTIG Research lifted their target price on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Raymond James raised their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Truist Financial increased their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Finally, Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Stock Down 0.6 %

NASDAQ:ISRG traded down $2.42 on Thursday, hitting $398.48. The stock had a trading volume of 754,583 shares, compared to its average volume of 1,536,463. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $408.43. The business’s fifty day moving average is $386.00 and its 200 day moving average is $360.92. The company has a market cap of $141.34 billion, a PE ratio of 72.36, a P/E/G ratio of 5.19 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the business earned $1.00 EPS. The company’s quarterly revenue was up 11.5% on a year-over-year basis. Equities analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.